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Native mass spectrometry 
identifies an alternative DNA-
binding pathway for BirA from 
Staphylococcus aureus
Jiulia satiaputra1,3, Louise M. sternicki1, Andrew J. Hayes  1,4, Tara L. pukala  2, 
Grant W. Booker1, Keith E. shearwin1 & Steven W. Polyak  1,5
An adequate supply of biotin is vital for the survival and pathogenesis of Staphylococcus aureus. The 
key protein responsible for maintaining biotin homeostasis in bacteria is the biotin retention protein 
A (BirA, also known as biotin protein ligase). BirA is a bi-functional protein that serves both as a ligase 
to catalyse the biotinylation of important metabolic enzymes, as well as a transcriptional repressor 
that regulates biotin biosynthesis, biotin transport and fatty acid elongation. The mechanism of BirA 
regulated transcription has been extensively characterized in Escherichia coli, but less so in other 
bacteria. Biotin-induced homodimerization of E. coli BirA (EcBirA) is a necessary prerequisite for 
stable DNA binding and transcriptional repression. Here, we employ a combination of native mass 
spectrometry, in vivo gene expression assays, site-directed mutagenesis and electrophoretic mobility 
shift assays to elucidate the DNA binding pathway for S. aureus BirA (SaBirA). We identify a mechanism 
that differs from that of EcBirA, wherein SaBirA is competent to bind DNA as a monomer both in the 
presence and absence of biotin and/or MgATP, allowing homodimerization on the DNA. Bioinformatic 
analysis demonstrated the SaBirA sequence used here is highly conserved amongst other S. aureus 
strains, implying this DNA-binding mechanism is widely employed.
The biotin retention protein A (BirA, also known as biotin protein ligase) is responsible for maintaining biotin 
homeostasis in many bacteria. BirA is a bi-functional protein capable of both enzymatic protein biotinylation 
as well as serving as a biotin-controlled transcriptional repressor that regulates the expression of the biotin bio-
synthesis operon (reviewed1,2). By combining both activities in a single protein, BirA is uniquely placed as the 
key regulator of biotin metabolism. E. coli BirA (EcBirA) has been thoroughly investigated through genetic, bio-
chemical and structural biology studies3–11. These have provided powerful insights into the maintenance of biotin 
homeostasis. EcBirA binds to its ligands, biotin and ATP, in an ordered manner6,12. Conformational changes 
induced by biotin binding create the pocket necessary for ATP to bind. ATP binding initiates the synthesis of 
biotinyl-5′-AMP, which serves as both a reaction intermediate for biotin ligation as well as a co-repressor. The 
BirA:biotinyl-5′-AMP complex, known as the holo-enzyme, is then available for two alternative activities: either 
as a biotin protein ligase when there is a substrate available for protein biotinylation or when demand for biotin is 
low, as a transcriptional repressor through homodimerization13. The transcriptional repressor function of EcBirA 
involves a co-operative interaction between two EcBirA subunits and an inverted palindromic repeat sequence 
present in the promoter of the biotin biosynthetic operon (bioO). Homodimerization of the holo-enzyme 
complex (KD2-1 = 1–6 × 10−6 M14,15) is a pre-requisite for DNA binding4,5,16,17. The unliganded enzyme (i.e. 
apo-EcBirA) does not dimerize at physiological concentrations (KD2-1 = 1 × 10−3 M14) and is unable to bind 
DNA9,17. Mutagenesis studies have further highlighted the importance of homodimerisation in the DNA binding 
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mechanism. Amino acid substitutions that promote homo-dimerization display increased affinity for DNA and 
function as super-repressors18,19. Conversely, replacing key amino acids in the interface between the two EcBirA 
subunits disrupts dimerization, and eliminates DNA-binding activity7,15,17,20,21. One well-characterized example 
is EcBirA-R119W20,22 (Supporting Fig. S1A) that is essentially monomeric in solution (KD2-1 = 2 × 10−2 M17). This 
dimerization-impaired mutant thus mimics the association state of apo-EcBirA.
S. aureus BirA (SaBirA) shares many features with its E. coli homologue. The two proteins have similar ter-
tiary structures despite limited sequence conservation (24% identity, 42% similarity, Supporting Fig. S1B). Both 
proteins undergo analogous conformational changes that define the ordered ligand binding mechanism23–25. Like 
EcBirA, SaBirA is a biotin-dependent transcriptional repressor of biotin biosynthesis26,27. Unlike EcBirA how-
ever, SaBirA regulates expression of additional operons - the substrate specific subunit of the biotin transporter 
(encoded by bioY), and the yhfS-yhfT operon encoding putative homologs of acetyl-CoA acetyl transferase and 
long-chain fatty acid-CoA ligase, respectively26,28. Holo-SaBirA binding directly to the promoter sequence of the 
biotin biosynthesis operon (SabioO) has recently been demonstrated by us24,26,29, and others27. Estimates of the 
dissociation constant (KD), based on polyacrylamide gel-based electrophoretic mobility shift assays (EMSA), 
suggest a 6-fold difference in the affinity for DNA between apo and holo-SaBirA (apo 649 nM, holo 108 nM29). 
In support of these results, fluorescence anisotropy experiments performed in solution suggest the holo-protein 
binds 63-fold tighter to DNA than the apo-protein (apo 5 μM, holo 83 nM27). The modest differences in affinity 
for the apo enzyme are likely due to polymorphisms in the SaBirA sequences used in the two studies. Despite 
the intrinsic DNA-binding activity of the apo enzyme, SaBirA has been shown to function as a biotin-dependent 
transcriptional repressor26,27. These observations are significantly different to EcBirA, where apo-protein is devoid 
of DNA-binding activity.
In this study, the homodimerisation and DNA-binding activities of EcBirA and SaBirA were investigated using 
in vivo reporter assays and in vitro biochemical analysis. For the first time, native mass spectrometry was utilized 
to study the self-association and DNA binding functions of BirA. Nano-electrospray ionization-mass spectrom-
etry (nESI-MS) performed under native conditions is an ideal technique for studying BirA as the soft ionization 
employed maintains non-covalent interactions during the transit from solution to gas phase30. This permitted the 
direct detection of biotinyl-5′-AMP binding to BirA, as well as quantitating the stoichiometry of the protein:DNA 
complexes. Engineered protein mutants designed to disrupt homodimerization, namely EcBirA-R119W and the 
S. aureus equivalent SaBirA-F123G (Supporting Fig. S1), were also employed to address the requirement for pro-
tein dimerization on DNA-binding (in vitro) and transcriptional repression (in vivo). Together these data revealed 
that monomeric SaBirA is competent to bind DNA and, once bound, can recruit a second protein subunit. This 
new pathway is not evident with EcBirA. Bioinformatic analysis identified that the SaBirA enzyme used in this 
study, from the methicillin and vancomycin resistant S. aureus strain Mu50, is the prototypical BirA amongst the 
S. aureus species. We propose that this DNA binding mechanism may be widely used amongst S. aureus.
Results
Biotin-induced repression of transcription. Apo-SaBirA has been shown to bind DNA in vitro27,29. We 
sought to address if the non-liganded protein possessed repressor activity in an in vivo assay of gene expression. 
As it is technically challenging to achieve the apo-state in vivo, we employed the SaBirA-F123G mutant that 
impairs homo-dimerization and, therefore, mimics the monomeric properties of the non-liganded protein29. 
Wild-type EcBirA and SaBirA, and the dimerization disrupted EcBirA-R119W mutant31, were used as controls. 
Biotin-induced repressor activity was measured using a bacterial reporter system we have previously described26 
and summarized in Fig. 1A. Briefly, a birA gene under the control of the pLac-UV5 promoter was site-specifically 
integrated into the lambda phage attachment site (attB) in the chromosome of a biotin auxotrophic strain of E. coli 
harboring a mutant BirA that is unable to bind DNA26. The host strain also produces lac repressor from the strong 
LacIq promoter, allowing us to repress expression of the BirA variants down to the low concentrations necessary 
for a physiologically relevant assay. A second construct containing a BirA-target promoter fused to a lacZ reporter 
gene was then integrated into the HK022 attB phage attachment site. Here, the promoters for bioO from both E. 
coli (EcbioO) and S. aureus (SabioO) were analyzed alongside promoters for the bioY and the yhfS-yhfT operon 
in S. aureus26. Biotin-mediated gene control was then assayed using β-galactosidase activity as a readout for gene 
expression. The effect of exogenous biotin on these genetic circuits, engineered into the genome of a strain unable 
to synthesis its own biotin, was measured by the addition of biotin to the growth media.
The in vivo reporter assay was developed to reconstitute the biotin-induced transcriptional repressor activity 
of BirA. Previous studies have suggested that E. coli contains ≈10–20 molecules of BirA per cell32. Therefore, the 
assay was designed to minimize artefactual binding to DNA due to the overexpression of BirA. Our previous 
work has demonstrated that the level of lac repressor provided from a single copy pLacIq-lacI module is able 
to very significantly, though not completely, repress a single copy plac-UV5 promoter module33. As expected, 
biotin-regulated repression of β-galactosidase was observed when IPTG was omitted from the growth media - 
implying the low level of leaky expression from the repressed lacUV5 promoter provided sufficient SaBirA for 
activity. Conversely, addition of 10 μM IPTG induced much higher expression of SaBirA, as detected by Western 
blot, and also abolished biotin-regulated control of the reporter (Supporting Fig. S2). Similarly, the level of EcBirA 
expression obtained in the absence of IPTG was shown to progressively inhibit β-galactosidase expression with 
increasing levels of biotin present in the growth media, as expected (Fig. 1B). Hence, all in vivo experiments were 
performed in the absence of IPTG (Fig. 1B–E).
The concentrations of biotin required to achieve half-maximum repression at equilibrium (Rbio) were calcu-
lated for each protein (Table 1). For E. coli, half maximal repression was achieved with 3.8 nM biotin. Likewise, 
biotin-induced repression was similar for all three S. aureus target promoters, with 7–10 nM biotin required for 
the same level of response (Table 1). Consistent with previous literature, the EcBirA-R119W mutant that lacks 
homo-dimerisation activity22,31 was also devoid of repressor activity in vivo (Fig. 1B, green symbols) yielding 
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similar levels of β-galactosidase expression as the no-repressor control (Fig. 1B, grey symbols). In contrast, 
SaBirA-F123G repressed activity against all three target promoters in a biotin-dependent manner (Fig. 1C–E, 
purple curves). For SabioO and SayhfS-yhfT, the Rbio values were 2.6-fold and 2.3-fold higher for SaBirA-F123G 
than wild-type protein, respectively (Table 1) (p = 0.07 WT vs F123G for SabioO; p = 0.2, WT vs F123G for 
SayhfS-yhfT). This modest decrease in repressor activity is consistent with a 3-fold higher KM for biotin that 
has been reported for SaBirA-F123G relative to the wild-type enzyme29. For SabioY, an accurate estimate of Rbio 
was not achieved as 500 nM of biotin was insufficient to completely inhibit expression down to the background 
level necessary to generate a concentration-dependent repression curve. At the lowest biotin concentration tested 
(1 nM), β-galactosidase expression from the SabioO and SayhfS-yhfT promoters was significantly lower than the 
Figure 1. In vivo β-galactosidase assays to measure biotin-induced repression. (A) Overview of E. coli reporter 
strains containing chromosomally integrated reporters. (B–E) β-galactosidase assays revealing biotin-induced 
repression by EcBirA (orange circles), EcBirA-R119W (green squares), SaBirA (blue circles) or SaBirA-F123G 
(purple squares). Target promoter sequences investigated were (B) EcbioO, (C) SabioO, (D) SabioY or (E) 
SayhfS-yhfT. Strains with no integrated BirA served as controls (grey triangles). A further control lacking an 
integrated promoter was used to measure the background lacZ activity at each biotin concentration (≤10 units), 
which has been subtracted to give values shown in the graphs. Error bars denote S.E.M from independent 
biological replicates (n = 6).
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corresponding no-repressor controls (Fig. 1C,E, wild-type blue and SaBirA-F123G purple vs control grey sym-
bols) implying both the wild-type and SaBirA-F123 mutant proteins partially occupied the DNA under these 
conditions. Together this data suggests monomeric SaBirA (a mimic of the apo-state) is capable of repressing its 
target genes, which is not evident with EcBirA.
In vitro analysis of apo and holo-BirA oligomeric states. The molecular basis of the unexpected 
repressor activity observed with SaBirA-F123G was further investigated using biochemical assays. Wild-type 
EcBirA and SaBirA were purified in their apo-forms alongside the two dimerization-impaired mutant proteins 
EcBirA-R119W and SaBirA-F123G. Removal of biotin from the recombinant proteins was achieved by incubat-
ing cell lysates (containing over-expressed protein) with streptavidin-Sepharose to remove excess biotin, before 
incubation with a biotin-accepting substrate protein to facilitate protein biotinylation and the concomitant loss 
of biotinyl-5′-AMP from the BirA active site prior to IMAC purification. The apo-state of the four proteins was 
addressed using two alternative techniques that independently confirmed that all preparations were devoid of 
any co-purified biotinyl-5′-AMP; a streptavidin-blot method we have previously described29 (Supporting Fig. S3) 
and native nESI-MS that has not been employed previously for the study of BirA. The Streptavidin-blot assay 
failed to detect biotinyl-transferase activity for all four proteins, as expected for an apo-enzyme. In support, the 
masses measured by nESI-MS for the apo-preparations were as expected for monomeric BirA devoid of ligand 
(Fig. 2A,C,E and G and Supporting Table S4). We confirmed that the mild conditions employed with the native 
mass spectrometry studies allowed the direct measurement of BirA in complex with biotinyl-5′-AMP, as well as 
the oligomeric state of holo-BirA (Fig. 2B,D,F and H). The addition of biotin and MgATP to EcBirA and SaBirA 
resulted in the detection of two species (Fig. 2B,F), consistent with those expected for the monomeric proteins 
bound to the reaction intermediate biotinyl-5′-AMP (EcBirA, measured 36771 Da, theoretical molecular mass 
36765 Da: SaBirA, measured 38470 Da, theoretical molecular mass 38466 Da) and the dimeric form of these 
ligand-bound complexes (EcBirA, measured 73559 Da, theoretical molecular mass 73530 Da: SaBirA: measured 
76925 Da, theoretical molecular mass 76931 Da). The nESI-MS data confirmed that EcBirA and SaBirA pos-
sessed biotinyl-5′-AMP synthetase activity, and the enzyme:biotinyl-5′-AMP complex was stable following their 
exchange into the volatile 200 mM ammonium acetate pH 6.85 buffer required for mass spectrometry. Incubation 
of EcBirA-R119W and SaBirA-F123G with biotin and MgATP yielded single species with masses consistent with 
monomers in complex with biotinyl-5′-AMP (EcBirA-R119W, measured 36783 Da, theoretical molecular mass 
36795 Da: SaBirA-F123G, measured 38381 Da, theoretical molecular mass of 38376 Da). There was no evidence of 
biotin-induced homodimers for either mutant protein (Fig. 2D,H). This demonstrated that whilst EcBirA-R119W 
and SaBirA-F123G retained biotinyl-5′-AMP synthetase activity, both had abolished in-solution dimerization 
activity.
Apo and dimerization-impaired SaBirA are competent to bind DNA. Native nESI-MS (Fig. 3) 
was employed to probe the DNA binding activities of EcBirA and SaBirA. Oligonucleotides containing the rec-
ognition sequences from the EcbioO and S. aureus bioY promoters were employed for the nESI-MS analysis. 
DNA:protein complexes were formed in 200 mM ammonium acetate pH 6.9 buffer by incubating BirA with the 
double-stranded oligonucleotides on ice for at least one hour prior to mass spectrometry analysis. A comparison 
of the theoretical and measured molecular masses for the complexes analysed in this study is shown in Supporting 
Table S5. The specificity of the BirA:DNA interaction was initially confirmed using an oligonucleotide lacking 
BirA operators. Neither native nESI-MS nor EMSA detected SaBirA binding to an oligonucleotide with the two 
BirA half sites mutated to random sequences (Supporting Fig. S4).
For holo-EcBirA, the predominant species had a mass consistent with two subunits of EcBirA bound to DNA. 
For the apo-EcBirA protein, this species was seen only with weak intensity (Fig. 3A,B). For EcBirA-R119W (at 
a protein concentration of 10 μM) biotinyl-5′-AMP also induced a complex comprising two protein subunits 
on DNA, a species which was only observed with a weak intensity for apo-EcBirA-R119W (Fig. 3C,D). At equi-
librium, the majority of the apo-wild-type EcBirA and EcBirA-R119W was present as monomeric protein, not 
in complex with DNA. Consistent with the nESI-MS datum, DNA binding was also observed in an EMSA for 
wild-type holo EcBirA (Fig. 4A). However, holo-EcBirA-R119W mutant binding to DNA could not be measured 
by EMSA, even at 400 nM BirA (Fig. 4B).
Promoter
Repression constant (Rbio) nM
Wild-type Dimerization-impaired mutant
EcbioO 3.8 ± 0.6 >500
SabioO 7.0 ± 0.3 18.6 ± 5.6
SabioY 6.1 ± 2.6 >500
SayhfS-yhfT 10.0 ± 2.0 22.6 ± 9.7
Table 1. In vivo equilibrium binding constants for biotin-induced transcriptional repression. The concentration 
of biotin required to achieve half-maximum repression (Rbio) at equilibrium in the β-galactosidase reporter 
assay was calculated from the data presented in Fig. 1B–E. Data was fitted using the one-site specific binding 
equation Y = Bmax*Xh/(Rbioh + Xh), where Y = LacZ units, X = biotin concentration (nM), Bmax = maximum 
binding (LacZ units) and h = Hill-slope (BirA binding as a homodimer, h = 2). Datum is from six independent 
experiments.
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For the SaBirA, evidence of two protein subunits in complex with DNA was observed for wild-type and 
mutant SaBirA-F123G, in both apo and holo-states (Fig. 3E–H). In both apo-samples minimal free protein was 
observed, implying most of the SaBirA was in a complex with DNA. This was in contrast to apo-EcBirA where 
free protein was readily detected. This datum was consistent with EMSA results where both holo-wild-type 
and holo-SaBirA-F123G were competent to bind DNA (Fig. 4C–H). The EMSA analysis also revealed the 
holo-wild-type SaBirA binds all three target promoters at similar affinities (Fig. 4C–E). However, the interaction 
between holo-SaBirA-F123G and Sa yhfS-yhFT was clearly weaker compared to the SabioO and SabioY operator 
sequences (Fig. 4E–G) which is likely due to a base pair mismatch in the BirA binding site26. Together these find-
ings highlight a key difference between the E. coli and S. aureus BirAs – monomeric (i.e. apo) SaBirA is capable 
of stable binding to DNA.
Figure 2. Native nano-electrospray ionization-mass spectrometry determination of the oligomeric state of 
wild-type BirA and dimerization-impaired mutants. nESI-MS spectra of (A) apo-EcBirA, (B) holo-EcBirA, (C) 
apo-EcBirA-R119W, (D) holo-EcBirA-R119W, (E) apo-SaBirA, (F) holo-SaBirA, (G) apo-SaBirA-F123G and 
(H) holo-SaBirA-F123G. Peaks revealing the oligomeric state of the proteins are marked by the sphere symbols 
and are annotated with the corresponding charge states. Monomers are denoted by a single sphere, homodimers 
are shown by two joined-spheres and the presence of biotinyl-5′-AMP is represented with a black triangle.
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Figure 3. Native nano-electrospray ionization-mass spectrometry analysis of BirA binding to DNA. nESI-MS 
spectra demonstrating the protein:DNA interaction involving (A) apo-EcBirA, (B) holo-EcBirA, (C) apo-
EcBirA-R119W and (D) holo-EcBirA-R119W bound to EcbioO and (E) apo-SaBirA, (F) holo-SaBirA, (G) 
apo-SaBirA-F123G and (H) holo-SaBirA-F123G bound to SabioY. Monomers are denoted by a single sphere, 
homodimers are shown by two joined-spheres and the presence of biotinyl-5′-AMP is represented with a black 
triangle. Black lines represent double stranded oligonucleotides containing two BirA binding sites (orange). 
Peaks corresponding to the major species are annotated with their charge state. The DNA sequences of the 
oligonucleotides used in the assay are shown below with the two half sites highlighted in red.
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Ordered assembly of BirA on DNA. The ordered assembly of SaBirA on DNA was finally addressed by 
native nESI-MS using a SabioO oligonucleotide that contained a single half site (Fig. 5, Supporting Table S7). 
The apo-SaBirA sample revealed a species consistent with one monomer bound to DNA with a charge state 
distribution centered around 13+ and 14+ (Fig. 5A). However, no DNA-bound dimer was observed. In con-
trast, holo-SaBirA revealed free dimer and a species consistent with two holo-SaBirA subunits in complex with 
DNA (Fig. 5B). Therefore, under high biotin conditions holo-SaBirA can dimerise prior to binding DNA, such as 
occurs with EcBirA. Like the wild-type protein, apo-SaBirA-F123G was also competent to bind DNA as a single 
BirA subunit (Fig. 5C). Holo-SaBirA-F123G was able to bind as a single subunit bound to DNA and well as a 
complex of two protein subunits bound to the mutated SabioO oligonucleotide (Fig. 5D). This datum suggests 
that once a single subunit of SaBirA is bound, a second subunit can subsequently bind and stabilize the complex. 
This DNA-induced protein dimerization can proceed despite the inability of SaBirA-F123G to dimerise in solu-
tion. EMSA analysis did not detect holo-SaBirA binding to the mutated oligonucleotide containing only a single 
BirA binding site (Supporting Fig. S6). It is likely that the experimental conditions of an EMSA, whereby a pro-
tein:DNA complex must endure slow (minutes to hours) electrophoretic separation, may not favour the relatively 
short lived interactions that native nESI-MS can measure on the millisecond timescale. Thus, the native nESI-MS 
data strongly suggests a pathway where SaBirA dimers can assemble on the DNA one subunit at a time.
Bioinformatic analysis of S. aureus BirA sequences. Several groups have now reported studies char-
acterising BirA from S. aureus24,25,27,29,34. However, these studies have used genes encoding birA that have been 
cloned from different strains bearing different sequences making it difficult to directly compare the findings 
between studies. It was necessary to identify a consensus SaBirA sequence as detailed studies on the E. coli homo-
logue have demonstrated that substitution of certain amino acids can disrupt networks of long-range bonding 
interactions that can effect homodimerization, DNA binding and transcriptional repression despite not being 
localized to the dimer interface nor DNA binding domain (Fig. 6A)18,19,21,35. To identify the most conserved BirA 
homolog amongst S. aureus, BirA protein sequences were obtained using available genomic datum. A multiple 
sequence alignment was performed upon 26 non-redundant SaBirA sequences (Supporting Fig. S7), including 
Mu50 (used in this study and in24,29,34), Newman (used in the experiments reported in25,27) and the well-studied 
NCTC 8325 strain. The alignment indicated that the sequence of Mu50 BirA is highly represented amongst the S. 
aureus genomes analysed. The Mu50 sequence differs from both the Newman and NCTC 8325 strains, specifically 
at positions 247 (R247 in Mu50, I247 in Newman and NCTC 8325) and 272 (I272 in Mu50, T272 in Newman 
and NCTC 8325) (Fig. 6B,C). Out of the 26 unique sequences analysed, 20 possessed arginine at 247 (conserved 
with Mu50) and 22 species had isoleucine at position 272 (conserved with Mu50). These residues are located 
within the central catalytic domain of SaBirA, within α-helical structures (R247 in α-helix 8 and I272 in α-helix 
9, Supporting Fig. S8). Neither residue is implicated in interactions with the substrates, biotin or ATP, nor are they 
located close to the dimerization interface. However, it is possible these residues may influence long range bond-
ing interactions that can influence protein dimerization and DNA binding. Noteworthy is a tyrosine at position 
Figure 4. Electrophoretic mobility shift assays. EMSA of the interaction between EcbioO and (A) EcBirA or (B) 
EcBirA-R119W. Also shown is SaBirA binding to (C) SabioO, (D) SabioY or (E) SayhfS-yhfT and SaBirA-F123G 
binding to (F) SabioO, (G) SabioY and (E) SayhfS-yhfT. Concentrations of enzyme used in the binding reactions 
are indicated. Panels C, D and E showing wild type SaBirA binding are from26. Full length gels are presented in 
Supporting Fig. S5.
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182 that was conserved in 25 strains including Mu50 and Newman, but which is a phenylalanine in NCTC 8325. 
Recent studies have reported that substitution of the equivalent tyrosine in EcBirA (Y178) disrupts an electro-
static network of binding interactions that alters protein dimerization18,19. As the Mu50 sequence employed here 
is the most highly representative homologue amongst S. aureus, this sequence should be considered the prototyp-
ical SaBirA in future experiments.
Discussion
In certain bacteria BirA is a bifunctional protein that is both a biotin protein ligase and transcriptional repressor 
of biotin biosynthesis. The biosynthesis of biotin is metabolically costly, requiring the activity of at least four gene 
products and 20 ATP equivalents per biotin molecule36. Therefore, the activity of BirA allows cells to find the 
necessary balance between cellular demand, supply from the environment and de novo synthesis. Here we study 
the BirA protein from two clinically important bacteria, namely E. coli and S. aureus. E. coli is considered the pro-
totypical bacteria, and its BirA protein has been the subject of many biochemical, structural and genetic studies. 
The S. aureus homologue has not been investigated in as much detail. The two bacteria colonize different micro 
niches where the availability of environmental biotin is distinctive. E. coli is a part of the intestinal microflora 
which contributes to the synthesis and release of substantial amounts of biotin. Recent mouse studies estimate the 
concentration of biotin in the ileum to be 450–700 nM37. Conversely, S. aureus possess the extraordinary ability to 
colonise a wide range of niche microenvironments and is responsible for various disorders affecting the skin, res-
piratory organs, soft tissues, bones and joints. The bioavailability of biotin at these sites is lower than in the intes-
tine. Accordingly, we propose that S. aureus BirA has evolved unique properties that allow the bacteria to adapt to 
low biotin environments. In this study, we performed detailed in vivo and in vitro analyses to obtain new insights 
into the transcription regulation mechanisms of SaBirA. We utilized the SaBirA from the Mu50 methicillin and 
vancomycin resistant strain of S. aureus38. Our bioinformatics analysis has demonstrated this particular variant of 
SaBirA represents the most conserved SaBirA sequence among S. aureus strains. Furthermore, Mu50 SaBirA has 
been the target for the discovery of new classes of antibiotics designed to treat MRSA infections23,39–41. We also 
performed our study alongside the well-characterized BirA from E. coli, in order to highlight the differences in 
dimerization and DNA-binding mechanisms between the two homologues.
Figure 5. Native nano-electrospray ionization-mass spectrometry analysis of SaBirA binding to DNA 
containing one binding site. nESI-MS spectra demonstrating the interaction between SabioO oligonucleotide 
containing only one BirA binding half site with (A) apo-SaBirA, (B) holo-SaBirA, (C) apo-SaBirA-F123G and 
(D) holo-SaBirA-F123G. Monomers are denoted by a single sphere, homodimers are shown by two joined-
spheres and the presence of biotinyl-5′-AMP is represented with a black triangle. Black lines represent double 
stranded oligonucleotides containing one BirA binding site (orange). The charged states of the major species are 
annotated on the spectra. The DNA sequences of the oligonucleotides used in the assay are shown below with 
the wild-type half sites highlighted in red and the mutated half site in bold text.
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Previous studies performed on Mu50 SaBirA revealed weak dimerization of the apo-form of this protein (KD2-1 = 
29 ± 0.2 μM)29 suggesting that in its apo-state, this protein is likely to be monomeric within the intracellular 
environment. Hence, we proposed that SaBirA-F123G, as a dimerization-deficient mutant in solution, would 
mimic the oligomeric state of this apo-SaBirA in vivo. Whilst the analogous E. coli mutant was clearly devoid 
of DNA-binding activity in vivo, as reported in the literature31 and seen here, our results clearly demonstrated 
SaBirA-F123G functioned as an effective transcriptional repressor for all three S. aureus target promoters in vivo. 
Furthermore, even at environmental biotin concentrations as low as 1 nM, wild-type SaBirA and SaBirA-F123G 
demonstrated some repression compared to the no repressor control. This phenomenon was in contrast to 
EcBirA. This suggests that SaBirA can either respond to lower concentrations of environmental biotin (unlikely 
since KM values for biotin are similar (0.3 ± 0.1 μM for EcBirA42 v 1.01 ± 0.16 μM for SaBirA23), or that SaBirA 
partially occupies the DNA even when biotin is limiting, and therefore, the protein is in the apo-state.
In vitro analysis supported the contention that the intrinsically monomeric SaBirA-F123G or wild-type 
apo-SaBirA can bind DNA, enabling in vivo repression. The Mu50 strain wild-type SaBirA used here was unable 
to dimerize in solution at a protein concentration of 10 µM in its apo-form, as indicated by native nESI-MS. This 
Figure 6. SaBirA sequence analysis. (A) Crystal structure of EcBirA [PDBID 2EWN6] highlighting amino 
acids that influence homodimerization when mutated. (B) 26 non-redundant SaBirA sequences were aligned 
to determine the consensus sequence (see Supporting Fig. S7 for full alignment). Differences between S. aureus 
strains Mu50, Newman and NCTC 8325 are shown here. The EcBirA sequence is also aligned (below) for 
comparison. C. Crystal structure of SaBirA [PDBID 4DQ223] showing the position of amino acids that are not 
conserved between S. aureus strains Mu50, Newman and NCTC8325.
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finding agrees with our previous work which has demonstrated the apo-protein to be monomeric by small angle 
X-ray scattering assay29 and crystallises as a single subunit24. It also agrees with recent work conducted on SaBirA 
from the Newman strain reported by Wang and Beckett25 where analytical ultracentrifugation (AUC) failed to 
detect homodimerization. This is in contrast to our previous AUC datum where dimerisation of apo-SaBirA 
from Mu50 was observed29. It should be noted that different protein sequences were employed between these 
two studies (discussed further below). Additionally, this may have been the result of contaminating co-repressor, 
biotinyl-5′-AMP, that was not detected by the Streptavidin blot method used to assay the purified protein27. Here, 
a superior technique of native nESI-MS has been utilized to unambiguously detect not only the oligomeric state of 
the protein, but to simultaneously determine whether these species are truly devoid of bound ligands. This is the 
first report where native mass spectrometry has been employed to study BirA. No dimeric form of SaBirA-F123G 
was observed in either the apo or holo forms in solution, supporting its characterization as a monomeric mutant.
Furthermore, our results suggest dimerization of apo-SaBirA and SaBirA-F123G is mediated by DNA 
binding, as native nESI-MS detected species with molecular weights equivalent to two monomers of SaBirA 
in complex with the SabioY recognition sequence oligonucleotide. Likewise, nESI-MS revealed wild-type and 
SaBirA-F123G bound a DNA probe containing only a single half site in both the apo and holo-states but with 
different stoichiometry equivalents. Whilst the apo-proteins only bind as one subunit, biotinyl-5′-AMP allows 
the dimerization of wild-type SaBirA prior to DNA binding but also allowed SaBirA-F123G to dimerise on the 
DNA, despite not detectably dimerising in solution. The binding of SaBirA-F123G to DNA agrees with previous 
studies on apo-SaBirA where the KD for DNA binding was 6-fold lower compared to holo-SaBirA as measured by 
EMSA29, and 60-fold lower as measured by fluorescence anisotropy27.
By combining our in vitro and in vivo data, we propose two possible pathways for SaBirA to assemble on DNA, 
as illustrated in Fig. 7. In high biotin conditions, protein dimerization occurs in solution and precedes DNA 
binding, as has been well documented for EcBirA5,7. The pre-formed homodimer orients the two helix-turn-helix 
motifs present in the N-terminus of the protein such that they can simultaneously occupy both half sites on the 
target operator. Here we present evidence that binding to DNA can also proceed via the sequential assembly of 
two monomers onto the DNA, a pathway which is much less preferred for EcBirA. This alternative pathway is 
likely be the basis for the lower biotin threshold required to initiate the transcriptional repression observed with 
SaBirA compared to EcBirA, as highlighted in a previous study26 and seen with the partial occupation of SaBirA 
on DNA causing repression at low biotin concentrations (1 nM) in the in vivo reporter assay26. Whilst the DNA 
mediated dimerization pathway has been observed with the SaBirA from the Mu50 strain, which we have identi-
fied here as the prototypical example in S. aureus, it remains to be seen whether BirA from other species behave in 
a similar manner. The findings from this study may provide new insights into how biotin-regulated gene expres-
sion occurs in S. aureus allowing it to adapt to the low biotin environments it colonises.
Our bioinformatics analysis has identified multiple polymorphisms amongst S. aureus strains which may 
give rise to BirA variants with different homo-dimerization and DNA binding activities. Mutagenesis studies 
that target specific amino acids in EcBirA, together with structural biology and biophysical assays, are help-
ing to understand mechanisms of allosteric communication between distant sites in the protein and the impact 
upon their function18,21,35. Noteworthy is mutation of tyrosine 178 to cysteine (equivalent to Y182 in S. aureus 
Mu50, and F182 in NCTC 8325) that results in a super-repressor phenotype in whole cell reporter assays of 
transcription18. This amino acid does not reside directly in the dimer interface but, instead, contributes to com-
plex network of electrostatic interactions that are proposed to influence the structural alignment of the central 
(ligand-binding) and N-terminal (DNA-binding) domains of BirA that effect homo-dimerization and DNA bind-
ing19. Examination of available crystal structures of the Mu50 SaBirA23,24,29 likewise revealed that Y182 contrib-
utes to a network of electrostatic interactions involving K176 (that resides in a conserved KWPND motif in the 
active site) and D322 that resides in the DNA binding domain. Our analysis of genomic information also identi-
fied two differences in the BirA proteins from Mu50 and Newman at positions 247 and 272. Mutational studies, 
such as those performed to characterise the EcBirA mutants18,19, are required to probe the structure-function 
relationships in more detail. We propose that the SaBirA variants identified here present a useful system with 
which to further probe long distance modulation of protein allostery.
Figure 7. Proposed DNA binding pathway of SaBirA. In biotin-limiting conditions, BirA cannot dimerise 
in solution. However, SaBirA monomers (blue ovals) can bind to individual half sites (orange boxes), with 
the interaction presumably stabilized by interaction between the monomers on the DNA. Under high biotin 
conditions (biotin is indicated by a black triangle), SaBirA follows the same binding mechanism as holo-EcBirA, 
where a pre-formed dimer binds to DNA (light orange shading).
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Methods
Materials. E. coli strain JD26186 (bioC::Kan), based on host strain KP7600, is a transposon-disrupted bioC 
biotin auxotroph, and was obtained from the National BioResource Project (NIG, Japan). Bacteria were cultured 
at 37 °C with vigorous shaking in Luria Bertani media containing the appropriate antibiotic. Plasmid extractions 
were performed using the Plasmid QIAprep Spin Miniprep Kit (Qiagen) and genomic extractions were per-
formed using the Wizard® Genomic DNA purification kit (Promega). All molecular biology enzymes (DNA pol-
ymerase, ligases and restriction enzymes) and buffers were supplied by New England Biolabs. Oligonucleotides, 
purchased from Geneworks Ptd Ltd, are shown in Supporting Table S1.
Nucleic acid manipulations. All plasmids employed in this study are shown in Supporting Table S2. 
Site directed mutagenesis (Quikchange Site Directed Mutagenesis kit, Stratagene), was performed upon plas-
mid pGEM-EcBirA-H629 using oligonucleotides B460 and B461, yielding pGEM-EcBirA-R119W-H6. The 
EcbirA-R119W-H6 coding region was subsequently cloned into either pET16b (Novagen) for recombinant pro-
tein expression, or the integration vector pIT4_TL_15200243, yielding pIT4_TL_EcBirA-R119W-H6. Similarly, 
the SabirA-F123G-H6 coding region was excised from pGEM-SaBirA-F123G-H629 and ligated into pIT4_
TL_152002, yielding pIT4_TL_SaBirA-F123G-H6.
Generation of bacterial strains for in vivo reporter assays. All strains of E. coli employed in this study 
are shown in Supporting Table S3. β-galactosidase reporter assays were performed on E. coli reporter strains gen-
erated in26. Both the β-galactosidase reporters and the BirA expression modules were site-specifically integrated 
in the chromosome in single copy (Fig. 1A). BirA binding sequence was cloned into pLacZ_SHTrim plasmid 
upstream of the β-galactosidase reporter gene. BirA expression (EcBirA, SaBirA and their dimerization defec-
tive mutants EcBirA-R119W and SaBirA-F123G) was under control of the placUV5 promoter. These were con-
structed using the methods outlined in26,44. The β-galactosidase reporter assays were conducted as described43,45.
Protein methods. Recombinant expression of all BirA proteins employed in this study, as well as their puri-
fication by immobilized metal ion affinity chromatography (IMAC), were performed essentially as previously 
described29,34. However, the following modifications were included to ensure removal of biotinyl-5′-AMP from 
the protein preparations. Prior to IMAC purification, the cell lysate was incubated at 4 °C for a minimum of 
1 hour with 10 μL 50% slurry Streptavidin-sepharose High Performance (GE Healthcare Life Sciences) per mil-
lilitre of lysate. This was centrifuged at 4000 rpm, 4 °C for 10 minutes, to remove the resin. The cleared lysate was 
then incubated for 1 hour at 37 °C with 6 mg biotin-accepting substrate GST-SaPC90 per 10 ml of lysate prior to 
IMAC. Purified proteins were dialyzed overnight in 4 L of storage buffer (50 mM Tris pH 8.0, 100 mM KCl, 1 mM 
DTT, 5% (v/v) glycerol) and stored at −80 °C until required. Protein SDS-PAGE was performed using NuPageTM 
Bis-Tris 4–12% gels (Invitrogen).
Native nano-electrospray ionisation-mass spectrometry (nESI-MS). Purified BirA proteins were 
buffer exchanged into 200 mM ammonium acetate pH 6.85 (Sigma) using Amicon Ultra-0.5 MWCO 10,000 
centrifugal filter units (Merck Millipore). Holo-enzyme samples (at least 100 µM, except for EcBirA-R119W that 
was 30 µM) were prepared by pre-incubating the apo-proteins with 500 µM biotin, 1 mM ATP and 1 mM MgCl2 
on ice for at least 1 hour prior to buffer exchange. HPLC-purified and annealed, double stranded oligonucleo-
tides containing the operator sequences of interest were purchased from Integrated DNA Technology (USA). 
These were desalted into 200 mM ammonium acetate using Illustra MicroSpin G-25 columns (GE Healthcare). 
Oligonucleotide concentrations were quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific). 
Proteins were quantified following buffer exchange via Bradford assay, and then diluted to 10 µM in 200 mM 
ammonium acetate for analysis by nESI-MS. Protein:DNA complexes were analyzed by nESI-MS after diluting 
the oligonucleotide and protein in 200 mM ammonium acetate pH 6.9 to 5 µM and 10 µM respectively, and incu-
bating at 4 °C for at least 1 hour prior to MS analysis.
Mass spectrometry (MS) measurements were performed on a Synapt HDMS system (Waters, UK) with the 
sample introduced by nano-electrospray ionization in the positive ion MS mode from platinum-coated borosil-
icate capillaries prepared in-house. Instrument parameters were optimized to remove adducts while preserving 
non-covalent interactions, and were as follows; capillary voltage, 1.5 kV; cone voltage, 60 V; trap collision energy, 
20 V; transfer collision energy, 15 V; source temperature, 50 °C; backing pressure, 3.95 mbar. Data analysis was 
performed using manual peak finding in MassLynx software (version 4.1).
Electrophoretic mobility shift assay (EMSA). Binding reactions were performed at room tempera-
ture for 30 minutes using EMSA buffer (50 mM Tris pH 8.0, 50 mM NaCl, 0.1 mM biotin, 1 mM ATP, 1 mM 
MgCl2 and 10% (v/v) glycerol) together with 10 nM of the double stranded oligonucleotide (HPLC-purified as 
utilized for nESI-MS) and varying concentrations of BirA. Fractionation of the samples was performed using 
4–12% TBE polyacrylamide gels (Life Technologies) run at 100 volts (constant) for 45 minutes and stained in 
GelRed (Biotium) solution for 5 minutes. After washing five times in distilled water, the gels were imaged using 
a ChemiDoc imager (Bio-Rad). Each EMSA experiment was performed in triplicate.
S. aureus BirA multiple sequence alignment. BirA sequences of S. aureus were compared as fol-
lows: the protein cluster PCLA_885364 (accessed on 15/5/17) containing 71 entries (which encompasses all 
non-redundant proteins identified as biotin-acetyl-CoA-carboxylase ligase in the Genus Staphylococcus) was 
obtained from NCBI46,47 and further filtered for the clade Staphylococcus aureus 19988 to make a list of 26 unique 
protein sequences. These sequences were then aligned using Clustal Omega48. The alignment was then compared 
using UGENE49 and the position of the polymorphisms were mapped onto the SaBirA structure (PDB accession 
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4DQ223) using UCSF Chimera software (version 1.12). The EcBirA sequence for comparison was obtained from 
the PDB accession 2EWN6.
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